Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney

Launches With Preclinical Technology Platform Data

 
• By Mandy Jackson

Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.

Kidney care. Kidneys icon. World kidney day. Treatment of kidneys diseases.
Judo's platform knocks down disease-specific genes in the kidney • Source: Shutterstock

More from Financing

More from Leadership